HQH Stock Analysis: Tekla Healthcare Investors | NYSE
Asset Management | NYSE, USA | Market Cap: 1.334m USD | 12M Return: 64.5% | US87911J1034 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.36M
Qual. Beats: 1
Rev. Trend: -12.5%
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tekla Healthcare Investors (HQH) is a U.S.-domiciled closed-end equity mutual fund launched and managed by abrdn Inc. The fund invests in global public equity markets, primarily targeting growth-oriented small-cap companies within the healthcare sector, including biotechnology, medical devices, and pharmaceuticals. Portfolio construction is based on fundamental analysis, emphasizing factors such as market position, management quality, technological expertise, and access to capital.
The fund was formed on October 31, 1986, began trading on January 5, 1988, and benchmarks its performance against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. As a closed-end fund, HQH issues a fixed number of shares that trade on the NYSE like common stock, with its market price typically diverging from its net asset value based on supply and demand.
- Biotech rally lifts portfolio NAV above benchmark
- Small-cap healthcare rotation widens NAV discount
- Fed rate path pressures long-duration biotech valuations
| Net Income: 443.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.0 > 0.02 and ΔFCF/TA 0.0 > 1.0 |
| NWC/Revenue: 4.21% < 20% (prev -0.90%; Δ 5.11% < -1%) |
| CFO/TA 0.01 > 3% & CFO 8.72m > Net Income 443.6m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 2.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.2m) vs 12m ago 6.63% < -2% |
| Gross Margin: 84.59% > 18% (prev 88.10%; Δ -3.51% > 0.5%) |
| Asset Turnover: 3.14% > 50% (prev 9.01%; Δ -5.87% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.00 (Total Current Assets 2.61m - Total Current Liabilities 1.21m) / Total Assets 1.14b |
| B: 0.10 (Retained Earnings 113.8m / Total Assets 1.14b) |
| C: 0.16 (EBIT TTM 173.0m / Avg Total Assets 1.06b) |
| D: 366.9 (Book Value of Equity 1.14b / Total Liabilities 3.10m) |
| Altman-Z'' = 386.7 = AAA |
As of August 23, 2026, the stock is trading at USD 24.39 with a total of 197,786 shares traded. Over the past week, the price has changed by +4.59%, over one month by +14.67%, over three months by +24.50% and over the past year by +64.48%.
Current recommended Stop Loss: 23.60 (which is 3.2% or 1.5 ATR below the current price).
Tekla Healthcare Investors has no consensus analysts rating.
P/E Trailing = 5.2936
P/S = 6.0319
P/B = 1.1906
Revenue TTM = 33.3m USD
EBIT TTM = 173.0m USD
EBITDA TTM = 173.0m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.33b USD (1.33b + (null Debt) - CCE 59.0)
Interest Coverage Ratio = unknown (Ebit TTM 173.0m / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.33b)
FCF Margin = 0.0% (FCF TTM 0.0 / Revenue TTM 33.3m)
Net Margin = 1.33k% (Net Income TTM 443.6m / Revenue TTM 33.3m)
Gross Margin = 84.59% ((Revenue TTM 33.3m - Cost of Revenue TTM 5.13m) / Revenue TTM)
Gross Margin QoQ = 69.90% (prev none%)
Tobins Q-Ratio = 1.17 (Enterprise Value 1.33b / Total Assets 1.14b)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 136.7m (EBIT 173.0m * (1 - 21.00%))
Current Ratio = 2.15 (Total Current Assets 2.61m / Total Current Liabilities 1.21m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 173.0m)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 41.88% (Net Income 443.6m / Total Assets 1.14b)
RoE = 41.84% (Net Income TTM 443.6m / Total Stockholder Equity 1.06b)
RoCE = 15.19% (EBIT 173.0m / Capital Employed (Total Assets 1.14b - Current Liab 1.21m))
RoIC = 12.00% (NOPAT 136.7m / Invested Capital 1.14b)
WACC = 8.32% (E(1.33b)/V(1.33b) * Re(8.32%) + (debt-free company))
Discount Rate = 8.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.81 | Cagr: 7.75%
[DCF] Fair Price = unknown (Cash Flow 0.0)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.73 | # QB: 1
Revenue Correlation: -12.47 | Revenue CAGR: -10.61% | SUE: N/A | # QB: 0